Gain Therapeutics, Inc. Common Stock
GANXGain Therapeutics, Inc. (GANX) is a biotechnology company focused on developing innovative treatments for rare and underserved diseases. Utilizing its proprietary allosteric modulation platform, the company aims to discover and develop therapeutics that target enzymes and other proteins involved in disease pathways. Gain Therapeutics emphasizes precision medicine approaches to address unmet medical needs.
Company News
Gain Therapeutics announced that President and CEO Gene Mack will participate in a virtual fireside chat and one-on-one meetings at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, 2026. The clinical-stage biotech company is advancing its lead candidate GT-02287 for Parkinson's disease treatment in a Phase 1b clinica...
Gain Therapeutics announced that CEO Gene Mack will participate in a fireside chat at the 38th Annual ROTH Conference on March 23, 2026. The company will also present additional clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease at AD/PD 2026, including interim analysis results. The company remains on track to...
Gain Therapeutics will participate in the 2025 Maxim Growth Summit, with CEO Gene Mack joining a panel discussion on neurodegenerative diseases and presenting their lead drug candidate GT-02287 for Parkinson's disease treatment.
Gain Therapeutics presented positive Phase 1 data for its lead drug candidate GT-02287, which showed an increase in GCase activity in healthy volunteers, supporting its potential as a disease-modifying treatment for Parkinson's disease.
Gain Therapeutics, a clinical-stage biotechnology company, will host a webinar to discuss positive results from a Phase 1 study of its lead drug candidate GT-02287 for Parkinson's disease and the design of an upcoming Phase 1b trial.
